Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 13/20 | 1.00 |
| ▸ | CA2 | P00918 | 13/20 | 1.00 |
| ▸ | CA9 | Q16790 | 11/20 | 1.00 |
| ▸ | CA12 | O43570 | 9/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | CA4 | P22748 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9953139 | 0.88 | CA2 (1.00) | CA1CA2CA9CA12LMNA | |
| SCHEMBL15312866 | 0.84 | CA2 (1.00) | CA1CA2CA9CA12LMNA | |
| SCHEMBL15312802 | 0.82 | CA1 (1.00) | CA1CA2CA9CA12LMNA | |
| SCHEMBL5312329 | 0.76 | LMNA (0.70) | CA1CA2CA9CA12LMNA | |
| Potassium Ion SCHEMBL5317511 | 0.74 | LMNA (0.68) | CA1CA2CA9CA12LMNA | |
| SCHEMBL15024639 | 0.73 | LMNA (0.80) | CA1CA2CA9CA12LMNA | |
| SCHEMBL8432165 | 0.73 | LMNA (0.78) | CA1CA2CA9CA12LMNA | |
| SCHEMBL4319784 | 0.72 | LMNA (0.61) | CA1CA2CA9CA12LMNA | |
| SCHEMBL13241841 | 0.72 | MAPT (0.77) | ALDH1A1GAAMAPTKMT2A | |
| SCHEMBL942538 | 0.72 | LMNA (0.68) | CA1CA2CA9CA12LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150150849-A1 | CANCER TARGETING USING CARBONIC ANHYDRASE ISOFORM IX INHIBITORS | STICHTING MAASTRICHT RADIATION ONCOLOGY "MAASTRO- CLINIC" (NL) | 2015-06-04 | — | — | US | disclosed |
| US-8980932-B2 | Cancer targeting using carbonic anhydrase isoform IX inhibitors | Stichting Maastricht Radiation Oncology “Maastro-Clinic” (NL) | 2015-03-17 | — | — | US | disclosed |
| CN-103443083-A | Cancer Targeting Using Carbonic Anhydrase Isoenzyme IX Inhibitors | STICHTING MAASTRICHT RADIATION ONCOLOGY MAASTRO CLINIC | 2013-12-11 | — | — | CN | disclosed |
| EP-2655336-A1 | CANCER TARGETING USING CARBONIC ANHYDRASE ISOFORM IX INHIBITORS | STICHTING MAASTRICHT RADIATION ONCOLOGY "MAASTRO CLINIC" (NL) | 2013-10-30 | — | — | EP | disclosed |
| US-20130274305-A1 | CANCER TARGETING USING CARBONIC ANHYDRASE ISOFORM IX INHIBITORS | Supuran, Claudiu (IT) | 2013-10-17 | — | — | US | disclosed |
| WO-2012087115-A1 | CANCER TARGETING USING CARBONIC ANHYDRASE ISOFORM IX INHIBITORS | STICHTING MAASTRICHT RADIATION ONCOLOGY "MAASTRO-CLINIC" (NL) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150849-A1 | CANCER TARGETING USING CARBONIC ANHYDRASE ISOFORM IX INHIBITORS | CA9, HIF1AN, CA4 | CA1 9/4885CA2 5/4885CA9 1/4885 |
| US-20130274305-A1 | CANCER TARGETING USING CARBONIC ANHYDRASE ISOFORM IX INHIBITORS | CA9, HIF1AN, CA4 | CA1 9/4885CA2 5/4885CA9 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.